Back to 2024 Display ePosters
Mitral Valve Replacement With The Mitris Resilia Biological Prosthesis: Short-term Results
Andrea Amabile, James Antonios, Shiv Verma, Ajay Dharan, Syed Usman Bin Mahmood, Roland Assi, Arnar Geirsson, Markus Krane;
Yale School of Medicine, NEW HAVEN, CT, USA
BACKGROUND: The MITRIS RESILIA biological prosthesis (Edwards Lifesciences, Irvine, CA) combines the anti-calcification technology of the RESILIA bovine pericardial tissue with the low-profile, saddle-shaped design of the Carpentier-Edwards PERIMOUNT valve. To date, there are no retrospective studies investigating real-world outcomes and hemodynamics of the MITRIS RESILIA bioprosthesis.
METHODS: We performed a single-center, retrospective cohort study of all consecutive patients undergoing mitral valve replacement (MVR) with the MITRIS RESILIA biological prosthesis at a quaternary academic center. Information on demographics, comorbidities, intraoperative variables, short-term postoperative outcomes, and hemodynamics were retrieved from our institutional STS database as well as from direct review of electronic medical records.
RESULTS: Since the first implantation of the MITRIS RESILIA biological prosthesis at our Institution in May 2022, 25 consecutive patients underwent mitral valve replacement (MVR) with the MITRIS RESILIA biological prosthesis. Preoperative and intraoperative information are summarized in Table 1. Short-term outcomes were excellent, with no 30-day mortality and no need for reoperation. One patient (4%) underwent readmission for development of pleural effusion requiring drainage. No patient developed postoperative stroke (0%), one patient developed postoperative renal failure (4%), two patients developed pneumonia (8%), and three patients required permanent pacemaker implantation (12%). Median length of stay was 8 days (interquartile range, 5.75-14.75 days). Postoperative mean gradients are shown in Figure 1, stratified by prosthesis size.
CONCLUSIONS: This is the first retrospective study investigating real-world outcomes in patients undergoing MVR with the MITRIS RESILIA biological prosthesis. Our findings suggest that the MITRIS RESILIA prosthesis provides good postoperative hemodynamics across all valve sizes, with no short-term degeneration. Further studies are warranted to evaluate real-world mid-term and long-term outcomes.
Back to 2024 Display ePosters
